

## Faculty

### Nicolaus Andratschke

University Hospital Zurich, Switzerland

### Anna Berghoff

Medical University of Vienna, Austria

### Andrea Bink

University Hospital Zurich, Switzerland

### Stephanie Combs

Klinikum rechts der Isar, Munich,  
Germany

### Alessandra Curioni

University Hospital Zurich, Switzerland

### Matthias Guckenberger

University Hospital Zurich, Switzerland

### Emilie Le Rhun

University Hospital Zurich, Switzerland

### Giuseppe Minniti

Sant Andrea Hospital, Rome, Italy

### Marian Christoph Neidert

Kantonsspital St. Gallen, Switzerland

### Matthias Preusser

Medical University of Vienna, Austria

### Arjun Sahgal

Sunnybrook Health Sciences Centre,  
Toronto, Canada

### Hussein A. Tawbi

The University of Texas MD Anderson  
Cancer Center, Houston, Texas

### Michael Weller

University Hospital Zurich, Switzerland

## Information

### Organization

Comprehensive Cancer Center Zürich  
Rämistrasse 100  
8091 Zurich  
Switzerland

[www.cancercenter.usz.ch](http://www.cancercenter.usz.ch)

### Credits

SGMO 5  
SGPath tbd  
SNG 7  
SSRO 5

### Registration

until September 6th, 2021 at [3rd Zurich  
Brain Metastasis Symposium – Universi-  
tätsspital Zürich \(usz.ch\)](#) or [ccc@usz.ch](mailto:ccc@usz.ch)  
Registration is free of charge.

Follow University Hospital Zurich



Kindly supported by



virtual  
event

Comprehensive Cancer Center Zürich (CCCZ)

## 3rd Zurich Brain Metastasis Symposium

Wednesday, September 8th, 2021, 16.30 – 18.45 h  
Thursday, September 9th, 2021, 16.00 – 19.00 h

CCCZ – joint center of excellence



Der Balgrist



## Welcome

Dear colleagues

Advances in systemic targeted therapy and immunotherapy have dramatically improved outcome at least in some types of solid cancer. However, metastasis to the central nervous system remains a major diagnostic and therapeutic challenge, notably in long-term survivors with cancers.

Here we invite you to our 3rd Zurich Brain Metastasis Symposium that will provide state-of-the-art presentations on current and future diagnostic and therapeutic approaches for patients with brain and leptomeningeal metastasis.

We hope to welcome you to another successful symposium of the Comprehensive Cancer Center Zürich.



Michael Weller, Prof. Dr. med.  
Chairman Department of Neurology



Matthias Guckenberger, Prof. Dr. med.  
Outreach and Education, CCCZ

## Program Wednesday, September 8th

- 16.30 h**    **Welcome**  
Chairs: Michael Weller, University Hospital Zurich /  
Matthias Guckenberger, University Hospital Zurich
- 16.35 h**    **EANO / ESMO practice guideline for brain metastases**  
Emilie Le Rhun, University Hospital Zurich
- 17.05 h**    **Advances in diagnostics:  
imaging for differentiating radionecrosis, pseudoprogression and  
true progression**  
Andrea Bink, University Hospital Zurich
- 17.35 h**    **Advances in systemic therapy:  
Novel immunological treatment options**  
Anna Berghoff, Medical University of Vienna
- 18.00 h**    **Advances in local therapy:  
pre versus post-surgical radiotherapy**  
Arjun Sahgal, Sunnybrook Health Sciences Centre, Toronto, Canada  
Marian Christoph Neidert, Kantonsspital St. Gallen
- 18.35 h**    **Wrap-up**

## Program Thursday, September 9th

- 16.00 h**    **Welcome**  
Chairs: Michael Weller, University Hospital Zurich /  
Matthias Guckenberger, University Hospital Zurich
- 16.05 h**    **Sequencing of SRS and systemic therapy – Background**  
Matthias Guckenberger, University Hospital Zurich
- 16.35 h**    **Sequencing of SRS and systemic therapy – breast cancer**  
Emilie Le Rhun, University Hospital Zurich  
Giuseppe Minniti, Sant Andrea Hospital, Rome, Italy
- 17.10 h**    **Sequencing of SRS and systemic therapy – lung cancer**  
Alessandra Curioni, University Hospital Zurich  
Nicolaus Andratschke, University Hospital Zurich
- 17.45 h**    **Sequencing of SRS and systemic therapy – melanoma**  
Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center,  
Houston, TX, Stephanie Combs, Klinikum rechts der Isar, Munich
- 18.20 h**    **Challenges of clinical trial design for patients with brain metastasis**  
Michael Weller, University Hospital Zurich
- 18.50 h**    **Wrap-up**